Trial Profile
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Obsessive-compulsive disorders; Tic disorders
- Focus Therapeutic Use
- 04 Aug 2022 Status changed from active, no longer recruiting to completed.
- 12 May 2022 Planned End Date changed from 1 Apr 2022 to 31 May 2022.
- 12 May 2022 Planned primary completion date changed from 1 Apr 2022 to 31 May 2022.